These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19152217)

  • 1. Early toxicity screening strategies.
    Greene N; Naven R
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):90-7. PubMed ID: 19152217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive toxicology in drug development.
    Norman P
    Drug News Perspect; 2003 May; 16(4):254-6. PubMed ID: 12942155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing toxicity risk when designing and selecting compounds in early drug discovery.
    Segall MD; Barber C
    Drug Discov Today; 2014 May; 19(5):688-93. PubMed ID: 24451294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity.
    Van Summeren A; Renes J; van Delft JH; Kleinjans JC; Mariman EC
    Toxicol In Vitro; 2012 Apr; 26(3):373-85. PubMed ID: 22274661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of organ toxicity endpoints by QSAR modeling based on precise chemical-histopathology annotations.
    Myshkin E; Brennan R; Khasanova T; Sitnik T; Serebriyskaya T; Litvinova E; Guryanov A; Nikolsky Y; Nikolskaya T; Bureeva S
    Chem Biol Drug Des; 2012 Sep; 80(3):406-16. PubMed ID: 22583392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of new chemical entities with decreased potential for adverse drug reactions.
    Park KB; Dalton-Brown E; Hirst C; Williams DP
    Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity.
    Cruz-Monteagudo M; Cordeiro MN; Borges F
    J Comput Chem; 2008 Mar; 29(4):533-49. PubMed ID: 17705164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An expert system approach to the assessment of hepatotoxic potential.
    Marchant CA; Fisk L; Note RR; Patel ML; Suárez D
    Chem Biodivers; 2009 Nov; 6(11):2107-14. PubMed ID: 19937847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Ursem CJ; Kruhlak NL; Benz RD; Sabaté DA; Yang C; Klopman G; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):23-42. PubMed ID: 19422098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herbal hepatotoxicity.
    Stickel F; Patsenker E; Schuppan D
    J Hepatol; 2005 Nov; 43(5):901-10. PubMed ID: 16171893
    [No Abstract]   [Full Text] [Related]  

  • 13. Applying mechanisms of chemical toxicity to predict drug safety.
    Guengerich FP; MacDonald JS
    Chem Res Toxicol; 2007 Mar; 20(3):344-69. PubMed ID: 17302443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADMET in silico modelling: towards prediction paradise?
    van de Waterbeemd H; Gifford E
    Nat Rev Drug Discov; 2003 Mar; 2(3):192-204. PubMed ID: 12612645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicophore exploration as a screening technology for drug design and discovery: techniques, scope and limitations.
    Singh PK; Negi A; Gupta PK; Chauhan M; Kumar R
    Arch Toxicol; 2016 Aug; 90(8):1785-802. PubMed ID: 26341667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening.
    Siraki AG; Chevaldina T; Moridani MY; O'Brien PJ
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):118-25. PubMed ID: 14982155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avoiding idiosyncratic DILI: two is better than one.
    Kaplowitz N
    Hepatology; 2013 Jul; 58(1):15-7. PubMed ID: 23390057
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
    ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastrointestinal and hepatic side effects of drugs].
    Meier PJ; Fricker R
    Ther Umsch; 1987 Dec; 44(12):960-7. PubMed ID: 3327190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.